BioSpace News Archive

Stramsen Biotech Inc. is a Houston, Texas -based Biotechnology Company that currently has eleven new natural plant-based drug candidates for clinical development.

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today announced the commencement of its Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (“LAPC”) (AMP-270) following receipt of Institutional Review Board (“IRB”) approval for the trial protocol.

MapLight Therapeutics today announced it has completed its Phase 1 clinical trial evaluating ML-007, the second clinical compound developed using the MapLight platform. ML-007 is an M1/M4 muscarinic agonist that targets circuits thought to be disrupted in neurologic conditions such as schizophrenia and dyskinesia.

Almirall, LLC, a global biopharmaceutical company focused on skin health, announced its microtubule inhibitor ointment, KLISYRI® (tirbanibulin), a topical field treatment for actinic keratosis (AK) of the face and scalp, received a strong recommendation designation in the AAD’s American Academy of Dermatology’s Focused Update to the Guidelines of Care for the Management of Actinic Keratosis.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), today announces it has formed a Scientific Advisory Board (SAB) in support of the development of its lead therapeutic candidate QN-302 for the potential treatment of pancreatic cancer and other G4-prevalent solid tumors.

CYduct Diagnostics, Inc. today provides a corporate update and letter from President, Dominick Gatto.

TetraScience, the Scientific Data Cloud company, proudly announces its ISO 9001:2015 certification, which builds upon an ongoing corporate commitment to compliance and process formalization for biopharma customers.

The NORD® Rare Diseases & Orphan Products Breakthrough Summit® – the most highly anticipated, global rare disease conference of the year, every year – will be hosted on October 17 and 18, 2022 in Washington, DC.

The company is scaling up its US marketing in line with a 2022 growth plan that aims for significant growth in sales orders following commercial entry in 2021.

Think Bioscience has raised $17M in an oversubscribed Seed round led by Innovation Endeavors and Xora Innovation, with participation from AV8 Ventures, Buff Gold Ventures, and LiquidMetal Ventures.